NCT02909452 - Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 20, 2016

Primary Completion Date

July 17, 2019

Study Completion Date

February 9, 2021

Conditions

NeoplasmsNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsDigestive System NeoplasmsEndocrine Gland NeoplasmsCarcinoma, Non-Small-Cell LungLung DiseasesBreast DiseasesRenal NeoplasmSolid Tumors

Interventions

DRUG

Entinostat

HDAC (histone deacetylase) inhibitor

DRUG

Pembrolizumab

A selective humanized monoclonal antibody (mAb)

Trial Locations (1)

78229

The START Center for Cancer Care, San Antonio